Form 4 for PYXS Pyxis Oncology, Inc.
Accepted 2026-07-02 16:30:46 ET · period of report 2026-06-30 · accession 0001193125-26-294708 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-07-02 16:30 | 2026-06-30 | PYXS | Dupont Jakob | Dir | M - OptEx | $1.60 | +35.0K | 73.7K | +90% | +$56.0K |
| DT | 2026-07-02 16:30 | 2026-06-30 | PYXS | Dupont Jakob | Dir | S - Sale+OE | $3.06 | -35.0K | 38.7K | -47% | -$107.1K |
| DT | 2026-07-02 16:30 | 2026-06-30 | PYXS | Dupont Jakob | Dir | M - OptEx | $0.00 | -35.0K | 357.5K | -9% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-06-30 | M | A | 35,000 | $1.60 | 73,741 | D | — | — | |
| 2 | Common | Common Stock | 2026-06-30 | S | D | 35,000 | $3.06 | 38,741 | D | — | — | (F1) The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on Septemeber 24, 2025. (F2) Reflects sales of common stock executed in multiple transactions. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected within the ranges set forth in footnotes 3 of this Form 4. (F3) The transaction was executed in multiple trades in prices ranging from $3.00 to $3.36. |
| 3 | Derivative | Stock Option (Right to Buy) | 2026-06-30 | M | D | 35,000 | $0.00 | 357,461 | D | $1.60 · — to 2033-09-22 | 35,000 Common Stock | (F4) Award of stock options to purchase Common Shares with a vesting commencement date of August 23, 2024. These options vest and become exercisable in three equal annual tranches from August 23, 2023, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation). |